drugset / Trial / NCT07540832
Phase 2 Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCC
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with Lenvatinib, how the body processes and responds to WGI-0301, and whether this combination shows early signs of working in people with advanced liver cancer.
Timeline
- Start
- 2026-09
- Primary completion
- 2028-09
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |
| Subject | WGI-0301 | Antisense oligonucleotide | — | — |